Skip to content
Medical Health Aged Care

First proof that activation of receptors involved in the gut microbial breakdown of fibre cuts cardiovascular disease risk by 20 per cent

Monash University 2 mins read

A Monash University study of almost 400,000 people, published in the journal Cardiovascular Research, is the first to indicate, in humans, that the signalling of substances called short-chain fatty acids or SCFAs, released when gut bacteria break down dietary fibre, significantly protects against cardiovascular disease and hypertension by up to 20 per cent.  

A previous clinical trial by the Monash team, led by Professor Francine Marques, has shown that these SCFAs – when provided as a supplement – leads to lowered blood pressure. Another trial is underway (https://marqueslab.com/trials).

The current study used data from the UK Biobank database and found rare genetic variants that profoundly impact the function of receptors that bind to SCFAs essentially prevent people from utilising the cardiovascular-protection offered by their own gut microbes.

“We wanted to determine whether people with these genetic modifications had an increased risk of hypertension and major adverse cardiac events, including acute coronary syndrome, heart failure, and ischemic stroke,” said Professor Marques.

For this, the researchers compared individuals with these genetic variants and their cardiovascular medical history to controls, finding that this affected cohort had a significantly higher incidence of hypertension and long-term risk of cardiovascular disease, including heart attacks, heart failure and stroke.

Dr Leticia Camargo Tavares was the leading author of the study.

“The study found that disruption in these receptors is associated with up to 20 per cent increased prevalence of hypertension and heart disease or stroke – even after accounting for other risk factors like body weight and smoking,” Dr Tavares said.

“However, it is worth mentioning these rare genetic variants occur in less than 1 per cent of individuals,” Professor Marques said.

Importantly, the researchers also looked into what happened to this affected cohort – without the cardioprotective capacity – when fibre intake followed dietary guidelines. “If they consumed adequate dietary fibre, but were unable to turn this into protection against heart disease, then this would prove the importance of short-chain fatty acids signalling in cardio-protection,” Professor Marques said.

“Consistent with our hypothesis, the prevalence of hypertension was significantly higher in this cohort, even among those who ate a diet rich in fibre,” Dr Tavares added.

The research team is currently in the process of developing a commercially available product that can deliver SCFAs orally. In addition, the team aims to develop drugs that activate these receptors, which may provide a novel way to lower blood pressure and prevent heart disease. 

Read the full paper in Cardiovascular Research: Rare pathogenic variants in G-protein-coupled receptor genes involved in gut-to-host communication are associated with cardiovascular disease risk. DOI: 10.1093/cvr/cvaf070

 

For media enquiries please contact:

Monash University

Tania Ewing Media and Communications Contractor
E: [email protected] 

T: +61 (0) 408 378 422

For more Monash media stories, visit our news and events site  


For general media enquiries please contact:
Monash Media
E: [email protected]
T: +61 (0) 3 9903 4840

More from this category

  • Medical Health Aged Care
  • 17/02/2026
  • 23:10
Fortrea Holdings Inc

Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services

Adds to executive focus on early clinical development and deepens medical and scientific partnership with clientsDURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea’s chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strategy, scientific leadership, ethics and governance oversight across Fortrea’s portfolio. Scott Dove, PhD joins Fortrea as its new president of CPS, responsible for Fortrea’s early clinical development solutions…

  • Medical Health Aged Care, National News Current Affairs
  • 17/02/2026
  • 17:14
Private Healthcare Australia

Health insurance premiums to rise as healthcare costs and claims increase

Health insurance premiums will rise by an average of 4.41% from April 1, reflecting rising claims and higher costs of delivering healthcare. Private Healthcare Australia Chief Executive Dr Rachel David said health funds are working to balance the affordability of health insurance with the rising cost of providing quality care to an ageing population with increasingly complex chronic disease needs. The average premium increase for 2026 of 4.41% is lower than the rising cost of providing medical and hospital services, which rose 5 per cent last financial year. “More people are using their health insurance for high-cost hospital care such…

  • Medical Health Aged Care, Women
  • 17/02/2026
  • 15:05
The Collagen Co.

Collagen and Skin Ageing: How Your Skin Changes at Every Life Stage

Key Facts: Collagen production exceeds breakdown in youth but decreases by 1% annually from mid-20s, with accelerated loss post-menopause Early 20s focus should be…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.